198 related articles for article (PubMed ID: 7520089)
1. Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity.
Choi WS; Collignon C; Thiriart C; Burns DP; Stott EJ; Kent KA; Desrosiers RC
J Virol; 1994 Sep; 68(9):5395-402. PubMed ID: 7520089
[TBL] [Abstract][Full Text] [Related]
2. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.
Burns DP; Collignon C; Desrosiers RC
J Virol; 1993 Jul; 67(7):4104-13. PubMed ID: 8510218
[TBL] [Abstract][Full Text] [Related]
3. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.
Glamann J; Burton DR; Parren PW; Ditzel HJ; Kent KA; Arnold C; Montefiori D; Hirsch VM
J Virol; 1998 Jan; 72(1):585-92. PubMed ID: 9420262
[TBL] [Abstract][Full Text] [Related]
4. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
[TBL] [Abstract][Full Text] [Related]
5. Antigenic variation of SIV: mutations in V4 alter the neutralization profile.
Kinsey NE; Anderson MG; Unangst TJ; Joag SV; Narayan O; Zink MC; Clements JE
Virology; 1996 Jul; 221(1):14-21. PubMed ID: 8661410
[TBL] [Abstract][Full Text] [Related]
6. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
[TBL] [Abstract][Full Text] [Related]
7. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
[TBL] [Abstract][Full Text] [Related]
8. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.
Javaherian K; Langlois AJ; Montefiori DC; Kent KA; Ryan KA; Wyman PD; Stott J; Bolognesi DP; Murphey-Corb M; Larosa GJ
J Virol; 1994 Apr; 68(4):2624-31. PubMed ID: 7511176
[TBL] [Abstract][Full Text] [Related]
9. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.
McKeating JA; Shotton C; Cordell J; Graham S; Balfe P; Sullivan N; Charles M; Page M; Bolmstedt A; Olofsson S
J Virol; 1993 Aug; 67(8):4932-44. PubMed ID: 7687306
[TBL] [Abstract][Full Text] [Related]
10. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.
Johnson WE; Morgan J; Reitter J; Puffer BA; Czajak S; Doms RW; Desrosiers RC
J Virol; 2002 Mar; 76(5):2075-86. PubMed ID: 11836385
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251.
Matsumi S; Matsushita S; Yoshimura K; Javaherian K; Takatsuki K
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):501-8. PubMed ID: 7632464
[TBL] [Abstract][Full Text] [Related]
12. Production and characterization of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins.
Babas T; Le Grand R; Dormont D; Bahraoui E
AIDS Res Hum Retroviruses; 1997 Sep; 13(13):1109-19. PubMed ID: 9282816
[TBL] [Abstract][Full Text] [Related]
13. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
14. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
[TBL] [Abstract][Full Text] [Related]
15. Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus.
Watkins JD; Diaz-Rodriguez J; Siddappa NB; Corti D; Ruprecht RM
J Virol; 2011 Dec; 85(23):12811-4. PubMed ID: 21957314
[TBL] [Abstract][Full Text] [Related]
16. Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4.
Pikora C; Wittish C; Desrosiers RC
J Virol; 2005 Oct; 79(19):12575-83. PubMed ID: 16160185
[TBL] [Abstract][Full Text] [Related]
17. Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins.
Kent KA; Gritz L; Stallard G; Cranage MP; Collignon C; Thiriart C; Corcoran T; Silvera P; Stott EJ
AIDS; 1991 Jul; 5(7):829-36. PubMed ID: 1716442
[TBL] [Abstract][Full Text] [Related]
18. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.
Kent KA; Rud E; Corcoran T; Powell C; Thiriart C; Collignon C; Stott EJ
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1147-51. PubMed ID: 1380261
[TBL] [Abstract][Full Text] [Related]
19. Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant.
Nyambi PN; Lewi P; Peeters M; Janssens W; Heyndrickx L; Fransen K; Andries K; Vanden Haesevelde M; Heeney J; Piot P; van der Groen G
J Virol; 1997 Mar; 71(3):2320-30. PubMed ID: 9032368
[TBL] [Abstract][Full Text] [Related]
20. Alanine substitution of two arginines in amino terminus of V3 of SIV disrupts CD4 binding whereas a similar replacement of two amino acids, lysine and arginine, in the carboxyl half of V3 prevents binding of a neutralizing monoclonal antibody.
Javaherian K; Zuchowski L; Clark FT
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1101-5. PubMed ID: 8554907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
